FDA Approves Epcoritamab-bysp for DLBCL

On May 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval to epcoritamab-bysp  for the treatment of adult patients with for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma and high-grade B-cell lymphoma after two or more lines of systemic therapy.

For more information read the FDA announcement and Genmab announcement.

Posted 5/22/2023